Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021
CME ACTIVITY - Synopsis

Plasmodium ovale wallikeri and P. ovale curtisi Infections and Diagnostic Approaches to Imported Malaria, France, 2013–2018

Valentin JosteComments to Author , Justine Bailly, Véronique Hubert, Cécile Pauc, Mathieu Gendrot, Emilie Guillochon, Marylin Madamet, Marc Thellier, Eric Kendjo, Nicolas Argy, Bruno Pradines, Sandrine Houzé, and on behalf of the French National Reference Center for Imported Malaria Study Group1
Author affiliations: Centre National de Référence du Paludisme, Paris, France (V. Joste, J. Bailly, V. Hubert, C. Pauc, N. Argy, S. Houzé); Université de Paris, Paris (N. Argy, S. Houzé); Laboratoire de Parasitologie-Mycologie, Paris (V. Joste, N. Argy, S. Houzé); Institut de Recherche Biomédicale des Armées, Marseille, France (M. Gendrot, M. Madamet, B. Pradines); Aix–Marseille Université, Marseille (M. Gendrot, M. Madamet, B. Pradines); Instituts Hospitalo–Universitaires Méditerranée Infection, Marseille (M. Gendrot, M. Madamet, B. Pradines); Centre National de Référence du Paludisme, Marseille (M. Madamet, B. Pradines); Sorbonne Université, Paris, France (M. Thellier, E. Kendjo)

Main Article

Table 3

Biologic and clinical characteristics of Plasmodium ovale wallikeri and P. ovale curtisi infections, France, January 2013–December 2018*

Characteristic P. ovale curtisi, n = 309 P. ovale wallikeri, n = 368 p value
Parasite density, parasites/µL, median (IQR) 4,500 (1,094–10,197) 3,970 (598–9,240) 0.112
Leucocyte count, G/L, median (IQR) 5.6 (4.4–7.1) 5.2 (4.1–6.5) 0.0501
Hemoglobin, g/L, median (IQR)
 127 (113–140)
 126 (114–139)
 0.855
Platelet count, G/L, median (IQR) 111 (84–145) 94 (70–130) <0.001
<75 56 (19.4) 104 (31)
75–150 168 (58.1) 174 (51.9) 0.003
>150
 65 (22.5)
 57 (17.1)
Severe thrombocytopenia 13 (4.5) 25 (7.5) 0.123
Diagnostic delay, d, median (IQR)
 5 (3–7)
 4 (2–7)
 0.583
Delay between return from endemic country and onset of symptoms, d, median (IQR) 72 (18–208) 34 (10–95) <0.001
<50 days
 87 (42.4)
 150 (59.5)
 <0.001
Symptoms
Fever 262 (95.6) 316 (97.8) 0.125
Arthralgia or myalgia 120 (54.8) 138 (57.7) 0.525
Asthenia 108 (58) 133 (61.3) 0.506
Headache 151 (68.6) 201 (75.3) 0.103
Anorexia 5 4
Diarrhea 13 18
Abdominal pain 28 29
Nausea 16 20
Vomiting 24 13
Cough
 6
 12
Clinical categorization 0.927
Uncomplicated malaria 293 (97.7) 335 (97.4)
Severe malaria 3 (1) 5 (1.5)
Asymptomatic
 4 (1.3)
 4 (1.1)
Admission to hospital 158 (55.4) 196 (60.3) 0.243
Duration of hospitalization, d, median (IQR) 2 (1–3) 3 (1–4) 0.0732
Intensive- or intermediate-care hospitalization 1 (2.2) 7 (11.3) 0.134
Conventional hospitalization
 46 (97.8)
 55 (88.7)
Treatment 0.00359
Chloroquine 147 (54.8) 152 (47.8)
Artemisinin therapy 46 (17.1) 93 (29.2)
Artemeter/lumefantrine 11 (25.5) 39 (41.9)
Artesunate 2 (4.3) 5 (5.4)
Arteminol/piperaquine 33 (70.2) 49 (52.7)
Atovaquone/proguanil 64 (23.9) 64 (20.1)
Mefloquine 3 (1.2) 0 (0)
Quinine 8 (3) 9 (2.9)

*Values are no. (%) patients except as indicated. IQR, interquartile range.

Main Article

1Additional members of the French National Reference Center for Imported Malaria Study Group who contributed data are listed at the end of this article.

Page created: January 04, 2021
Page updated: January 21, 2021
Page reviewed: January 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external